Search
Brecanavir
go.drugbank.com/drugs/DB04887InvestigationalBrecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV.
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigationalan action potential. … [L47122] This is due to the efficacy demonstrated in the pivotal Phase 3 MycarinG study (NCT03971422).[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973]
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigationalIn fact, pimavanserin is the first antipsychotic drug without D<sub>2</sub> blocking activity. … Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSebetralstat
go.drugbank.com/drugs/DB18305ApprovedInvestigationalHereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesCreatine
go.drugbank.com/drugs/DB00148ApprovedInvestigationalNutraceuticalAn amino acid derivative that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine.
Papaverine
go.drugbank.com/drugs/DB01113ApprovedInvestigationalAn alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. … The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.
Metyrapone
go.drugbank.com/drugs/DB01011ApprovedInvestigationalAn inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.
Categories: Cytochrome P-450 CYP2A6 Inhibitors, Cytochrome P-450 CYP3A InducersCurcuma xanthorrhiza oil
go.drugbank.com/drugs/DB11265ApprovedNutraceuticalFor centuries, _Curcuma xanthorrhiza_ oil has been used as a traditional medicine due to its antibacterial, antispasmodic, antioxidative, antitumor, anti-inflammatory and protective effects [A33160]. … _Curcuma xanthorrhiza_ oil is found as an active ingredient in cosmetic and hygienic products, and marketing of products containing _Curcuma xanthorrhiza_ oil is authorized in some European countries including
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalmanner[A218551] - this allows satralizumab to bind an IL-6 receptor until it reaches an endosome, after which the drug may dissociate from the receptor and move back into the plasma to act again. … satralizumab formulation developed by Chugai Pharmaceutical and Roche,[L15536] is uniquely formulated with "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a pH-dependent
Basiliximab
go.drugbank.com/drugs/DB00074ApprovedInvestigationalA recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also … It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes